Skip to main content

Plant and Fungal Extracts and Metabolites in Neurotherapy: Exploring Their Pharmacology and Potential Clinical Uses

Cover image for Research Topic "Plant and Fungal Extracts and Metabolites in Neurotherapy: Exploring Their Pharmacology and Potential Clinical Uses"
62kviews
Editorial06 May 2025
Editorial: Plant and fungal extracts and metabolites in neurotherapy: exploring their pharmacology and potential clinical uses

Central nervous system (CNS) disorders-including Alzheimer's disease, Parkinson's disease, spinal cord injury (SCI), stroke, and traumatic brain injury (TBI)-continue to impose profound clinical and societal burdens (Tsai et al., 2024). Despite decades of research and significant advancements in neuroscience, most therapeutic interventions remain largely palliative, addressing symptoms rather than altering the underlying course of disease progression (Gao et al., 2020). The multifactorial and heterogeneous nature of CNS pathologies presents considerable challenges to developing effective disease-modifying therapies. This therapeutic gap has catalyzed growing scientific interest in naturally derived bioactive metabolites, particularly phytochemicals and fungal metabolites. Long valued in traditional medical systems across diverse cultures, these metabolites are now being systematically explored for their neuroprotective, anti-inflammatory, antioxidant, and neuromodulatory properties (Ara et al., 2022). Their multi-target pharmacological profiles, combined with favorable safety, make them compelling candidates for CNS drug discovery and development. This special issue features a curated collection of studies that rigorously examine the therapeutic potential of plant-and fungus-derived metabolites across a range of CNS disease models, integrating ethnopharmacological knowledge with contemporary neuropharmacological approaches and methodologies. Several studies featured in this issue focus on cognitive impairment and proteinopathies within neurodegenerative contexts. Cheng et al. evaluated an ethanol extract of Rubia yunnanensis Diels (Rubiaceae) in a rat model of chronic cerebral hypoperfusion. Their findings revealed activation of the System Xc-/GSH/GPX4 antioxidant pathway and inhibition of ferroptosis, resulting in improved cognitive outcomes (Cheng et al., 2025). Similarly, Huang et al. demonstrated that Olea europaea L. (Oleaceae), a polyphenol metabolite extracted from olives, enhanced the proteasomal degradation of mutant huntingtin protein aggregates in Huntington's disease cell models, independent of autophagy pathways (Huang et al., 2024). These studies underscore the potential of phytochemicals to modulate oxidative stress and proteostasis-key processes implicated in the pathogenesis of neurodegenerative diseases. CNS trauma, including SCI and TBI, represents another major focus within this collection. Kooshki et al. reported that Pelargonium × hortorum L.H.Bailey (Geraniaceae), an anthocyanin metabolite, significantly improved motor function and alleviated neuropathic pain in a rat model of SCI, primarily through antioxidant and anti-inflammatory mechanisms (Kooshki et al., 2025). In a parallel study, Ma et al. developed a hydrogel-based drug delivery system for Daphne odora Thunb. (Thymelaeaceae), a coumarin metabolite with neuroprotective activity. In a murine TBI model, this system enhanced Daphne odora Thunb. (Thymelaeaceae) bioavailability, leading to improved spatial memory and reduced neuroinflammation (Ma et al., 2024). These studies highlight the value of innovative formulation strategies in optimizing the efficacy of natural metabolites for acute CNS injuries. Additional insights into SCI therapeutics are provided by Hao et al., who investigated the neuroprotective effects of rhein lysinate (RHL) (Hao et al., 2019). In SCI rats, RHL administration significantly improved motor function, increased the activity of endogenous antioxidant enzymes (SOD and GSH-Px), and reduced lipid peroxidation, as indicated by lower MDA levels. Mechanistically, RHL inhibited activation of the p38 MAPK signaling pathway, thereby attenuating neuronal apoptosis. These findings suggest that RHL promotes neuroprotection through the modulation of oxidative stress and apoptotic pathways.In a subsequent study, the same group demonstrated that Syringa vulgaris L. (Oleaceae), a lignan metabolite, facilitates functional recovery following SCI by activating the UBE4B/AKT signaling pathway. In glutamate-induced neurotoxicity models using SH-SY5Y cells, Syringa vulgaris L. (Oleaceae) upregulated UBE4B expression and enhanced AKT phosphorylation, resulting in reduced neuronal apoptosis. The protective effects were abolished by either UBE4B knockdown or AKT inhibition, confirming the critical role of this signaling axis (Hao et al., 2024). These findings reinforce the therapeutic relevance of the UBE4B/AKT pathway and underscore the broader potential of lignan metabolites in CNS repair and regeneration. Pain management, particularly for chronic and neuropathic pain, is another area where phytotherapeutics offer considerable promise. Wang et al. showed that Zingiber officinale Roscoe (Zingiberaceae), a bioactive metabolite derived from Zingiber officinale (ginger), mitigated inflammatory pain by suppressing neuronal excitability in the anterior cingulate cortex, suggesting a central mechanism of analgesia (Wang et al., 2025). Complementarily, Hashemi et al. reported that Haematococcus pluvialis Flotow (Haematococcaceae), a marine carotenoid metabolite, alleviated neuropathic pain in a chronic constriction injury model. Its mechanism of action involved both oxidative stress reduction and modulation of opioid and benzodiazepine receptor pathways, reflecting its multi-target pharmacological properties (Hashemi et al., 2024). Age-related cognitive decline and neuronal senescence were explored by Garg et al., who investigated Glycine max (L.) Merr. (Fabaceae), a soybean-derived oligopeptide. In a doxorubicin-induced hippocampal aging model, Glycine max (L.) Merr. (Fabaceae) activated the Wnt/β-catenin signaling pathway, suppressed senescence markers such as p16^INK4a and p21, and improved memory performance (Garg et al., 2025). Similarly, Wu et al. assessed the effects of Glycyrrhiza uralensis Fisch. ex DC. (Fabaceae) in a neonatal white matter injury model. The metabolite promoted oligodendrocyte maturation and reduced microglial activation through inhibition of histone deacetylase 3 (HDAC3), suggesting that phytochemicals may exert neuroprotective effects via epigenetic modulation (Wu et al., 2024). Sleep and mood disturbances, commonly observed in neurodegenerative and psychiatric disorders, were addressed by Li et al. using Eucalyptus globulus Labill. (Myrtaceae) (EEO) (Li et al., 2024). Their study demonstrated that EEO increased the levels of inhibitory neurotransmitters, including GABA and glycine, and modulated the composition of gut microbiota. These findings support the hypothesis that EEO exerts its sedative-hypnotic effects through gut-brain axis interactions, offering a novel mechanistic perspective on plantbased interventions for sleep disorders.Clinical evaluations of traditional botanical drug formulations were also featured. Chang et al. conducted a meta-analysis on the use of Sophora flavescens Aiton (Fabaceae) in patients experiencing bone neuropathic pain secondary to tumor metastasis. The analysis revealed significant reductions in pain severity and improvements in functional outcomes, validating its therapeutic potential in oncology-related pain management (Chang et al., 2024). Jiao et al. investigated the Yulinzhu botanical drug formula in women with polycystic ovary syndrome (PCOS), a condition involving neuroendocrine dysregulation (Jiao et al., 2024). Their findings demonstrated improvements in ovulation rates and hormonal profiles, indicating potential modulation of the hypothalamic-pituitary-gonadal axis. These results emphasize the systemic therapeutic potential of CNS-targeted phytomedicine in broader physiological contexts. Collectively, the contributions in this volume offer a comprehensive overview of recent progress in plant-and fungus-derived metabolites for CNS disorders. These studies address a wide spectrum of conditions-from neurodegeneration and trauma to chronic pain, neurodevelopmental injury, and neuroendocrine dysfunction-highlighting the ability of natural metabolites to influence key pathological processes such as oxidative stress, inflammation, apoptosis, proteostasis imbalance, and epigenetic dysregulation. Critically, while the studies in this volume have advanced our understanding of the therapeutic potential of plant-and fungus-derived metabolites, several limitations remain. Many investigations rely on preclinical models that do not fully capture the complexity of human CNS disorders, and standardized methodologies for the development of botanical drugs are still lacking. Moreover, the pharmacokinetic profiles and long-term safety of several metabolites have not been comprehensively evaluated. Future research should therefore prioritize the design and execution of robust clinical trials to validate these preclinical findings. Additionally, more in-depth mechanistic studies are needed to elucidate the molecular targets of these metabolites, and efforts should be made to optimize extraction, purification, and standardization protocols for botanical drugs. Interdisciplinary approaches that integrate ethnopharmacology, neurobiology, and advanced drug delivery systems will be crucial to translating these promising findings into effective therapeutic interventions. Such research topics will not only help bridge the gap between preclinical promise and clinical application but will also set the scene for further developments in CNS pharmacotherapy.

2,125 views

2 citations

Pelargonidin improves functional recovery and attenuates neuropathic pain following spinal cord injury in rats: relevance to its neuroprotective, antioxidant, and anti-inflammatory effects
BackgroundSpinal cord injury (SCI) significantly impairs individuals’ sensorimotor functions, hindering daily activities. Current therapeutic options often demonstrate limited efficacy and lead to undesirable side effects. Emerging research highlights the potential of anthocyanins, especially pelargonidin, which possess neuroprotective, anti-inflammatory, and antioxidant properties beneficial for neurological conditions.PurposeThis study sought to explore the impact of intrathecal administration of pelargonidin on the recovery of sensory-motor functions and associated disorders in a rat model of SCI through neuroprotective effects and regulating inflammatory/oxidative stress mediators.Materials and methodsIn total, 35 male Wistar rats were divided into five groups: sham, SCI, and three treatment groups receiving different intrathecal concentrations of pelargonidin (1, 2, and 4 mM) once on day 0 after surgery/injury. Weight changes were assessed and behavioral analyses were done, including hot plate tests, acetone drop tests, von Frey tests, inclined plane tests, as well as Basso, Beattie, and Bresnahan (BBB) scores, weekly up to day 28 post-injury. On day 28, serum levels of nitrite, catalase, and glutathione as well as matrix metalloproteinase (MMP) assays and histological evaluations were done.Results and discussionPelargonidin significantly attenuated neuropathic pain, improved motor performance, and reduced weight loss in rats with SCI. Biochemical assays demonstrated increased serum catalase/glutathione level, and MMP2 activity, while decreased serum nitrite level and MMP9 activity. Histological analyses showed an enhancement in the number of motor neurons in the ventral horn of the spinal cord after treatment with pelargonidin, highlighting its neuroprotective and neurogenic effects.ConclusionPelargonidin makes substantial therapeutic benefits following SCI by accelerating sensorimotor recovery. This effect is likely due to its strong antioxidant, anti-inflammatory, and neuroprotective properties.

2,988 views

9 citations

ORIGINAL RESEARCH
11 March 2025
Zingerone alleviates inflammatory pain by reducing the intrinsic excitability of anterior cingulate cortex neurons in a mice model
Yuanyuan Wang, 8 more and Jiandong Yu

2,885 views

7 citations

Neuroprotective effects of ethanol extraction from Rubia yunnanensis Diels on chronic cerebral hypoperfusion: modulation of the System Xc-/GSH/GPX4 axis to alleviate oxidative stress and ferroptosis
ORIGINAL RESEARCH
25 February 2025
Neuroprotective effects of ethanol extraction from Rubia yunnanensis Diels on chronic cerebral hypoperfusion: modulation of the System Xc-/GSH/GPX4 axis to alleviate oxidative stress and ferroptosis
Jianghao Cheng, 4 more and Xiaohua Duan
IntroductionVascular dementia (VD) is a neurodegenerative disease caused by chronic cerebral hypoperfusion (CCH), which considerably impact patients’ quality of life. Ethanol extraction from Rubia yunnanensis (RY-A) has gained attention for its potential neuroprotective effects, but its effects and mechanisms of action on CCH are unknown.MethodsAfter 30 days of RY-A gavage treatment in a CCH rat model, its effects were evaluated using the Morris water maze test, cerebral blood flow measurements, and HE staining of the brain. These findings, combined with serum medicinal chemistry, RNA-seq, and metabolomics analyses, revealed the active compounds and mechanisms of RY-A in CCH rats. The results were further validated using assay kits and Western blot techniques.ResultsRY-A treatment significantly attenuated neurological damage and improved cognitive function in CCH rats. Ultra-high-performance liquid chromatography high-resolution mass spectrometry identified 511 blood-entry compounds of RY-A. RNA-seq and metabolomic analysis showed that RY-A might help to normalize changes in gene and metabolite expression caused by CCH. RY-A induced neuroprotective effects by increasing the production of key proteins involved in ferroptosis inhibition, such as SLC7A11, SLC3A2, GSS, and GPX4, while increasing antioxidant enzyme activities and alleviating oxidative stress.ConclusionRY-A inhibited oxidative stress and ferroptosis by activating the System Xc-/GSH/GPX4 pathway and balancing iron metabolism, thereby attenuating CCH-induced neurological damage and cognitive deficits.

3,187 views

12 citations

ORIGINAL RESEARCH
25 February 2025
Exploring the potential anti-senescence effects of soybean-derived peptide Soymetide in mice hippocampal neurons via the Wnt/β-catenin pathway
Asmita Garg, 5 more and Sanghamitra Bandyopadhyay

4,718 views

8 citations

Anti-neuropathic effects of astaxanthin in a rat model of chronic constriction injury: passing through opioid/benzodiazepine receptors and relevance to its antioxidant and anti-inflammatory effects
ORIGINAL RESEARCH
25 November 2024
Anti-neuropathic effects of astaxanthin in a rat model of chronic constriction injury: passing through opioid/benzodiazepine receptors and relevance to its antioxidant and anti-inflammatory effects
Boshra Hashemi, 5 more and Javier Echeverría
Neuropathic pain is a debilitating neurological disorder and is on the rise. Since no effective treatment has been so far approved to combat the complex pathological mechanisms behind neuropathic pain, finding new therapeutic candidates is of great importance. Astaxanthin (AST) is a carotenoid with strong antioxidant, and anti-inflammatory activities. The present research aimed to evaluate the ameliorative effects of AST on a rat model of neuropathic pain.To induce neuropathic pain, a chronic constriction injury (CCI) model was employed.Accordingly, Wistar rats were divided into nine groups of six including sham, negative control group (CCI), positive control group gabapentin (100 mg/kg), AST (5, 10 mg/kg), flumazenil (0.5 mg/kg), naloxone (0.1 mg/kg), AST (10 mg/kg) + flumazenil (0.5 mg/kg), and AST (10 mg/kg) + naloxone (0.1 mg/kg) were administered intraperitoneally on days 1, 3, 5, 7, 10, and 14. To check the experimental signs of neuropathic pain and motor dysfunction, hot plate, acetone drop, and open field tests were used at the same time points. Additionally, biochemical assay and zymography were done on days 7 and 14 to assess the changes in catalase, glutathione and nitrite, as well as matrix metalloproteinases (MMP-2 and MMP-9). Besides, histological evaluations were performed for tissue damages on days 7 and 14.Results indicated that intraperitoneal injection of AST improved allodynia, hyperalgesia, and locomotor activity after CCI. AST also increased catalase and glutathione while suppressing nitrite, MMP-2, and MMP-9 activity through opioid/benzodiazepine receptors.The results highlighted AST as a promising candidate against neuropathic pain with beneficial effects on motor function by suppressing inflammatory mediators, and augmenting antioxidant factors, passing through opioid/benzodiazepine receptors.

4,336 views

17 citations

SYSTEMATIC REVIEW
19 November 2024
Meta-analysis of the effect of sophora flavescens on tumor metastasis-induced bone neuropathic pain
Cheng Chang, 6 more and Donghua Fan

3,093 views

Eucalyptus essential oil exerted a sedative-hypnotic effect by influencing brain neurotransmitters and gut microbes via the gut microbiota-brain axis
Sleep disorders are becoming more and more common, leading to many health problems.However, most of current available medications to treat sleep disorders are addictive and even impair cognitive abilities. Therefore, it is important to find a natural and safe alternative to treat sleep disorders. In this study, twenty-four 8-week-old male ICR mice (25 ± 2 g) were equally divided into three groups: the control group (gavage of 0.9% saline), the eucalyptus essential oil (EEO) group (10 mg/kg B.W.), and the diazepam group (1 mg/kg B.W.). Firstly, open field test and sleep induction test were used to determine the sedative-hypnotic effect of EEO. Secondly, the effect of EEO on neurotransmitters in the mice brain was determined. Finally, based on the gut microbiota-brain axis (GMBA), the effect of EEO on the intestinal flora of mice was explored. It was found that EEO significantly reduce the activity and prolong the sleep duration of mice, exhibiting a good sedative-hypnotic effect. In the brain, EEO could increase the levels of sleep-promoting neurotransmitters, such as glutamine, Gamma-aminobutyric acid (GABA), glycine, tryptophan, N-acetylserotonin, and 5-hydroxyindoleacetic acid (5-HIAA). In the intestine, EEO was found to increase the diversity of gut microbes, the abundance of short chain fatty acid (SCFA) producing flora, and the abundance of functional flora synthesizing GABA and glycine neurotransmitters. These studies suggested that EEO exerted a sedative-hypnotic effect by acting on gut microbes and neurotransmitters in the brain. EEO has the potential to become a natural and safe alternative to traditional hypnotic sedative drugs.

8,676 views

7 citations

ORIGINAL RESEARCH
11 September 2024
Isoliquiritigenin ameliorates abnormal oligodendrocyte development and behavior disorders induced by white matter injury
Dong Wu, 8 more and Aijun Hao

3,553 views

3 citations

SYSTEMATIC REVIEW
15 August 2024
Plant medicine metabolite Yulinzhu treating neurological disorder causing polycystic ovary syndrome: a systematic review and a meta-analysis
Beibei Jiao, 5 more and Weibo Zhao

3,738 views

4 citations

ORIGINAL RESEARCH
7 August 2024
RETRACTED: Topical application of daphnetin hydrogel for traumatic brain injury
Yuanhao Ma, 4 more and Jinyu Zheng

4,481 views

2 citations